The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer

The aim of this study was to analyse whether the level of tissue inhibitor of metalloproteinases (TIMP) 1 is associated with the tumour response and survival to preoperative radiochemotherapy in rectal cancer patients. Ninety-two patients with histologically confirmed non-metastatic rectal cancer of...

Full description

Saved in:
Bibliographic Details
Published in:Radiology and oncology 2013-06, Vol.47 (2), p.138-144
Main Authors: Oblak, Irena, Velenik, Vaneja, Anderluh, Franc, Mozina, Barbara, Ocvirk, Janja
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clinical outcomes
Colorectal cancer
Disease control
Enzyme-linked immunosorbent assay
Gender
Inhibitors
Medical prognosis
Metastases
Patients
Platelets
preoperative radiochemotherapy
prognostic factors
Proteases
Radiation therapy
rectal cancer
Rectum
Surgery
Survival
Tissue inhibitor of metalloproteinase 1
tissue inhibitor of metalloproteinases
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to analyse whether the level of tissue inhibitor of metalloproteinases (TIMP) 1 is associated with the tumour response and survival to preoperative radiochemotherapy in rectal cancer patients. Ninety-two patients with histologically confirmed non-metastatic rectal cancer of clinical stage I- III were treated with preoperative radiochemotherapy, surgery and postoperative chemotherapy. Plasma TIMP-1 concentrations were measured prior to the start of the treatment with an enzyme-linked immunosorbent assay (ELISA). Median follow-up time was 68 months (range: 3-93 months) while in survivors it was 80 months (range: 68-93 months). The 5-year locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) rates for all patients were 80.2%, 56.4%, 63.7% and 52.2%, respectively. The median TIMP-1 level was 185 ng/mL (range: 22-523 ng/mL) and the mean level (±standard deviation) was 192 (±87) ng/mL. Serum TIMP-1 levels were found to be significantly increased in patients with preoperative CRP>12 mg/L and in those who died from rectal cancer or had cT4 tumours. No correlation was established for age, gender, carcinoembriogenic antigene (CEA) level, platelets count, histopathological grade, response to preoperative therapy, resectability and disease reappearance. On univariate analysis, various parameters favourably influenced one or more survival endpoints: TIMP-1
ISSN:1318-2099
1581-3207
0485-893X
DOI:10.2478/raon-2013-0028